nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—CYP2C19—urine—nephrolithiasis	0.0157	0.127	CbGeAlD
Fluoxetine—Creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0148	0.0192	CcSEcCtD
Fluoxetine—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0139	0.018	CcSEcCtD
Fluoxetine—ALB—Scavenging of heme from plasma—AMBP—nephrolithiasis	0.0134	0.127	CbGpPWpGaD
Fluoxetine—CYP1A2—urine—nephrolithiasis	0.0129	0.104	CbGeAlD
Fluoxetine—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.0123	0.0159	CcSEcCtD
Fluoxetine—CYP2C9—urine—nephrolithiasis	0.0122	0.0988	CbGeAlD
Fluoxetine—Peptic ulcer—Hydrochlorothiazide—nephrolithiasis	0.0117	0.0151	CcSEcCtD
Fluoxetine—Blood creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0113	0.0147	CcSEcCtD
Fluoxetine—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.0108	0.014	CcSEcCtD
Fluoxetine—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.0105	0.0136	CcSEcCtD
Fluoxetine—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0102	0.0132	CcSEcCtD
Fluoxetine—HTR2A—urine—nephrolithiasis	0.01	0.0814	CbGeAlD
Fluoxetine—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.00992	0.0129	CcSEcCtD
Fluoxetine—Glycosuria—Hydrochlorothiazide—nephrolithiasis	0.00961	0.0125	CcSEcCtD
Fluoxetine—Numbness—Hydrochlorothiazide—nephrolithiasis	0.0094	0.0122	CcSEcCtD
Fluoxetine—CYP3A4—urine—nephrolithiasis	0.0093	0.0754	CbGeAlD
Fluoxetine—CYP2D6—urine—nephrolithiasis	0.00916	0.0742	CbGeAlD
Fluoxetine—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.00899	0.0117	CcSEcCtD
Fluoxetine—Jaundice cholestatic—Hydrochlorothiazide—nephrolithiasis	0.00887	0.0115	CcSEcCtD
Fluoxetine—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00868	0.0113	CcSEcCtD
Fluoxetine—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.0084	0.0109	CcSEcCtD
Fluoxetine—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.0084	0.0109	CcSEcCtD
Fluoxetine—Gout—Hydrochlorothiazide—nephrolithiasis	0.00834	0.0108	CcSEcCtD
Fluoxetine—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00824	0.0107	CcSEcCtD
Fluoxetine—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.00813	0.0105	CcSEcCtD
Fluoxetine—Vasculitis—Hydrochlorothiazide—nephrolithiasis	0.00798	0.0104	CcSEcCtD
Fluoxetine—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.00793	0.0103	CcSEcCtD
Fluoxetine—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00793	0.0103	CcSEcCtD
Fluoxetine—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00779	0.0101	CcSEcCtD
Fluoxetine—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00765	0.00993	CcSEcCtD
Fluoxetine—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.00735	0.00954	CcSEcCtD
Fluoxetine—Aplastic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00731	0.00949	CcSEcCtD
Fluoxetine—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.00712	0.00923	CcSEcCtD
Fluoxetine—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00704	0.00913	CcSEcCtD
Fluoxetine—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00704	0.00913	CcSEcCtD
Fluoxetine—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.00693	0.00899	CcSEcCtD
Fluoxetine—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00653	0.00847	CcSEcCtD
Fluoxetine—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.0065	0.00843	CcSEcCtD
Fluoxetine—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.00644	0.00835	CcSEcCtD
Fluoxetine—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00638	0.00827	CcSEcCtD
Fluoxetine—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.00632	0.0082	CcSEcCtD
Fluoxetine—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00626	0.00812	CcSEcCtD
Fluoxetine—Injury—Hydrochlorothiazide—nephrolithiasis	0.00615	0.00798	CcSEcCtD
Fluoxetine—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.0061	0.00791	CcSEcCtD
Fluoxetine—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00604	0.00784	CcSEcCtD
Fluoxetine—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00602	0.00781	CcSEcCtD
Fluoxetine—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00599	0.00777	CcSEcCtD
Fluoxetine—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00599	0.00777	CcSEcCtD
Fluoxetine—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00597	0.00774	CcSEcCtD
Fluoxetine—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00594	0.00771	CcSEcCtD
Fluoxetine—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.00594	0.00771	CcSEcCtD
Fluoxetine—Purpura—Hydrochlorothiazide—nephrolithiasis	0.00587	0.00761	CcSEcCtD
Fluoxetine—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00582	0.00755	CcSEcCtD
Fluoxetine—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00568	0.00736	CcSEcCtD
Fluoxetine—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00565	0.00733	CcSEcCtD
Fluoxetine—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00561	0.00728	CcSEcCtD
Fluoxetine—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00557	0.00722	CcSEcCtD
Fluoxetine—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00557	0.00722	CcSEcCtD
Fluoxetine—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00546	0.00708	CcSEcCtD
Fluoxetine—ALB—Binding and Uptake of Ligands by Scavenger Receptors—AMBP—nephrolithiasis	0.00537	0.0508	CbGpPWpGaD
Fluoxetine—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00536	0.00695	CcSEcCtD
Fluoxetine—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00532	0.0069	CcSEcCtD
Fluoxetine—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.00522	0.00677	CcSEcCtD
Fluoxetine—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00518	0.00672	CcSEcCtD
Fluoxetine—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00516	0.0067	CcSEcCtD
Fluoxetine—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00515	0.00667	CcSEcCtD
Fluoxetine—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00511	0.00663	CcSEcCtD
Fluoxetine—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00509	0.0066	CcSEcCtD
Fluoxetine—SIGMAR1—nephron tubule—nephrolithiasis	0.00508	0.0411	CbGeAlD
Fluoxetine—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.005	0.00649	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00499	0.00647	CcSEcCtD
Fluoxetine—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00499	0.00647	CcSEcCtD
Fluoxetine—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00492	0.00638	CcSEcCtD
Fluoxetine—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00489	0.00634	CcSEcCtD
Fluoxetine—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00489	0.00634	CcSEcCtD
Fluoxetine—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00479	0.00621	CcSEcCtD
Fluoxetine—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00476	0.00617	CcSEcCtD
Fluoxetine—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00457	0.00593	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00454	0.00589	CcSEcCtD
Fluoxetine—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00451	0.00586	CcSEcCtD
Fluoxetine—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0045	0.00584	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00446	0.00579	CcSEcCtD
Fluoxetine—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00445	0.00577	CcSEcCtD
Fluoxetine—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00441	0.00572	CcSEcCtD
Fluoxetine—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00438	0.00568	CcSEcCtD
Fluoxetine—SIGMAR1—cortex of kidney—nephrolithiasis	0.00435	0.0352	CbGeAlD
Fluoxetine—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00432	0.0056	CcSEcCtD
Fluoxetine—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.0043	0.00557	CcSEcCtD
Fluoxetine—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00428	0.00556	CcSEcCtD
Fluoxetine—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00427	0.00554	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00427	0.00554	CcSEcCtD
Fluoxetine—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00425	0.00551	CcSEcCtD
Fluoxetine—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00424	0.00549	CcSEcCtD
Fluoxetine—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00424	0.00549	CcSEcCtD
Fluoxetine—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00418	0.00542	CcSEcCtD
Fluoxetine—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00415	0.00539	CcSEcCtD
Fluoxetine—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00411	0.00533	CcSEcCtD
Fluoxetine—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00409	0.0053	CcSEcCtD
Fluoxetine—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00398	0.00516	CcSEcCtD
Fluoxetine—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00392	0.00509	CcSEcCtD
Fluoxetine—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00391	0.00507	CcSEcCtD
Fluoxetine—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00389	0.00505	CcSEcCtD
Fluoxetine—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00388	0.00504	CcSEcCtD
Fluoxetine—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00385	0.005	CcSEcCtD
Fluoxetine—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00377	0.00489	CcSEcCtD
Fluoxetine—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.0037	0.0048	CcSEcCtD
Fluoxetine—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00365	0.00473	CcSEcCtD
Fluoxetine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00349	0.00453	CcSEcCtD
Fluoxetine—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00346	0.00448	CcSEcCtD
Fluoxetine—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00336	0.00435	CcSEcCtD
Fluoxetine—Tension—Hydrochlorothiazide—nephrolithiasis	0.00334	0.00433	CcSEcCtD
Fluoxetine—CYP3A5—nephron tubule—nephrolithiasis	0.00334	0.027	CbGeAlD
Fluoxetine—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00333	0.00432	CcSEcCtD
Fluoxetine—CYP2B6—nephron tubule—nephrolithiasis	0.00332	0.0269	CbGeAlD
Fluoxetine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00331	0.00429	CcSEcCtD
Fluoxetine—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00329	0.00427	CcSEcCtD
Fluoxetine—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00327	0.00425	CcSEcCtD
Fluoxetine—HTR2C—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00322	0.0305	CbGpPWpGaD
Fluoxetine—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00319	0.00414	CcSEcCtD
Fluoxetine—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00316	0.0041	CcSEcCtD
Fluoxetine—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00315	0.00408	CcSEcCtD
Fluoxetine—CYP1A2—renal system—nephrolithiasis	0.00314	0.0255	CbGeAlD
Fluoxetine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00313	0.00406	CcSEcCtD
Fluoxetine—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00311	0.00404	CcSEcCtD
Fluoxetine—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00307	0.00398	CcSEcCtD
Fluoxetine—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00306	0.00397	CcSEcCtD
Fluoxetine—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00305	0.00396	CcSEcCtD
Fluoxetine—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00305	0.00395	CcSEcCtD
Fluoxetine—CYP3A5—renal system—nephrolithiasis	0.00303	0.0246	CbGeAlD
Fluoxetine—CYP2B6—renal system—nephrolithiasis	0.00301	0.0244	CbGeAlD
Fluoxetine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00301	0.0039	CcSEcCtD
Fluoxetine—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00299	0.00388	CcSEcCtD
Fluoxetine—Cough—Hydrochlorothiazide—nephrolithiasis	0.00297	0.00385	CcSEcCtD
Fluoxetine—CYP3A5—kidney—nephrolithiasis	0.00293	0.0238	CbGeAlD
Fluoxetine—CYP2B6—kidney—nephrolithiasis	0.00291	0.0236	CbGeAlD
Fluoxetine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.0029	0.00376	CcSEcCtD
Fluoxetine—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.0029	0.00376	CcSEcCtD
Fluoxetine—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.0029	0.00376	CcSEcCtD
Fluoxetine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00289	0.00375	CcSEcCtD
Fluoxetine—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00286	0.00371	CcSEcCtD
Fluoxetine—CYP3A5—cortex of kidney—nephrolithiasis	0.00286	0.0231	CbGeAlD
Fluoxetine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00284	0.00368	CcSEcCtD
Fluoxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00282	0.0267	CbGpPWpGaD
Fluoxetine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.0028	0.00363	CcSEcCtD
Fluoxetine—HTR2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0028	0.0265	CbGpPWpGaD
Fluoxetine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00278	0.0036	CcSEcCtD
Fluoxetine—Shock—Hydrochlorothiazide—nephrolithiasis	0.00273	0.00355	CcSEcCtD
Fluoxetine—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00272	0.00353	CcSEcCtD
Fluoxetine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00271	0.00352	CcSEcCtD
Fluoxetine—HTR2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00271	0.0257	CbGpPWpGaD
Fluoxetine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00269	0.00348	CcSEcCtD
Fluoxetine—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00265	0.00344	CcSEcCtD
Fluoxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00262	0.0248	CbGpPWpGaD
Fluoxetine—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00337	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00253	0.00328	CcSEcCtD
Fluoxetine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00251	0.00326	CcSEcCtD
Fluoxetine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00324	CcSEcCtD
Fluoxetine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00248	0.00321	CcSEcCtD
Fluoxetine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00247	0.0032	CcSEcCtD
Fluoxetine—HTR2A—renal system—nephrolithiasis	0.00246	0.0199	CbGeAlD
Fluoxetine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00245	0.00317	CcSEcCtD
Fluoxetine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00242	0.00313	CcSEcCtD
Fluoxetine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.0024	0.00311	CcSEcCtD
Fluoxetine—HTR2A—kidney—nephrolithiasis	0.00238	0.0193	CbGeAlD
Fluoxetine—Pain—Hydrochlorothiazide—nephrolithiasis	0.00238	0.00308	CcSEcCtD
Fluoxetine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00238	0.00308	CcSEcCtD
Fluoxetine—HTR2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00235	0.0223	CbGpPWpGaD
Fluoxetine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00229	0.00297	CcSEcCtD
Fluoxetine—CYP3A4—renal system—nephrolithiasis	0.00228	0.0184	CbGeAlD
Fluoxetine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00227	0.00295	CcSEcCtD
Fluoxetine—CYP2D6—renal system—nephrolithiasis	0.00224	0.0181	CbGeAlD
Fluoxetine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00221	0.00286	CcSEcCtD
Fluoxetine—CYP3A4—kidney—nephrolithiasis	0.0022	0.0178	CbGeAlD
Fluoxetine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.0022	0.00285	CcSEcCtD
Fluoxetine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.0022	0.00285	CcSEcCtD
Fluoxetine—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.0022	0.0208	CbGpPWpGaD
Fluoxetine—CYP2D6—kidney—nephrolithiasis	0.00217	0.0175	CbGeAlD
Fluoxetine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00266	CcSEcCtD
Fluoxetine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00199	0.00259	CcSEcCtD
Fluoxetine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00197	0.00255	CcSEcCtD
Fluoxetine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.0019	0.00247	CcSEcCtD
Fluoxetine—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00189	0.0179	CbGpPWpGaD
Fluoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00185	0.0175	CbGpPWpGaD
Fluoxetine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00184	0.00238	CcSEcCtD
Fluoxetine—ABCB1—nephron tubule—nephrolithiasis	0.00177	0.0144	CbGeAlD
Fluoxetine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00177	0.00229	CcSEcCtD
Fluoxetine—Rash—Hydrochlorothiazide—nephrolithiasis	0.00175	0.00227	CcSEcCtD
Fluoxetine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00175	0.00227	CcSEcCtD
Fluoxetine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00226	CcSEcCtD
Fluoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00169	0.016	CbGpPWpGaD
Fluoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00169	0.016	CbGpPWpGaD
Fluoxetine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00165	0.00214	CcSEcCtD
Fluoxetine—ABCB1—renal system—nephrolithiasis	0.00161	0.0131	CbGeAlD
Fluoxetine—ABCB1—kidney—nephrolithiasis	0.00156	0.0126	CbGeAlD
Fluoxetine—ABCB1—cortex of kidney—nephrolithiasis	0.00152	0.0123	CbGeAlD
Fluoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00128	0.0121	CbGpPWpGaD
Fluoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00128	0.0121	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Other—CHRM3—nephrolithiasis	0.00124	0.0118	CbGpPWpGaD
Fluoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00119	0.0113	CbGpPWpGaD
Fluoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00119	0.0113	CbGpPWpGaD
Fluoxetine—HTR2C—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00111	0.0105	CbGpPWpGaD
Fluoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00106	0.01	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00105	0.00997	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00105	0.00997	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000995	0.00943	CbGpPWpGaD
Fluoxetine—CYP1A2—Phase II conjugation—SLC26A1—nephrolithiasis	0.000995	0.00943	CbGpPWpGaD
Fluoxetine—CYP2B6—Biological oxidations—SLC26A1—nephrolithiasis	0.000988	0.00937	CbGpPWpGaD
Fluoxetine—CYP3A5—Biological oxidations—SLC26A1—nephrolithiasis	0.000966	0.00915	CbGpPWpGaD
Fluoxetine—HTR2A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000966	0.00915	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000938	0.00889	CbGpPWpGaD
Fluoxetine—ALB—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.000928	0.00879	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000864	0.00819	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000858	0.00813	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000858	0.00813	CbGpPWpGaD
Fluoxetine—ALB—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000849	0.00804	CbGpPWpGaD
Fluoxetine—ALB—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000849	0.00804	CbGpPWpGaD
Fluoxetine—HTR2C—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000804	0.00762	CbGpPWpGaD
Fluoxetine—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.000747	0.00708	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000719	0.00682	CbGpPWpGaD
Fluoxetine—HTR2A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000698	0.00662	CbGpPWpGaD
Fluoxetine—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000687	0.00651	CbGpPWpGaD
Fluoxetine—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	0.000681	0.00645	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00065	0.00616	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00065	0.00616	CbGpPWpGaD
Fluoxetine—ALB—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000643	0.00609	CbGpPWpGaD
Fluoxetine—ALB—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000643	0.00609	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000625	0.00592	CbGpPWpGaD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000622	0.00589	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000607	0.00575	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000605	0.00573	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000605	0.00573	CbGpPWpGaD
Fluoxetine—ALB—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000598	0.00566	CbGpPWpGaD
Fluoxetine—ALB—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000598	0.00566	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—SLC26A1—nephrolithiasis	0.000582	0.00551	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00054	0.00512	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000539	0.00511	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000539	0.00511	CbGpPWpGaD
Fluoxetine—ALB—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000533	0.00505	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000533	0.00505	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000529	0.00501	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000529	0.00501	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000471	0.00447	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.000469	0.00445	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000463	0.00439	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000463	0.00439	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000463	0.00438	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000449	0.00426	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000431	0.00409	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000431	0.00409	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000431	0.00408	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—RGS14—nephrolithiasis	0.000426	0.00404	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000413	0.00391	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000408	0.00386	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.000406	0.00384	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000378	0.00358	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000378	0.00358	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—PTH—nephrolithiasis	0.000371	0.00352	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—RGS14—nephrolithiasis	0.00037	0.00351	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000352	0.00334	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000327	0.0031	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000327	0.0031	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—PTH—nephrolithiasis	0.000322	0.00305	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.000317	0.003	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—SLC7A9—nephrolithiasis	0.000313	0.00296	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—DGKH—nephrolithiasis	0.000313	0.00296	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000304	0.00288	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000304	0.00288	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ADCY10—nephrolithiasis	0.000296	0.00281	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—DGKH—nephrolithiasis	0.000288	0.00273	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000286	0.00271	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000286	0.00271	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000275	0.00261	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000271	0.00257	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000271	0.00257	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000266	0.00252	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000266	0.00252	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ADCY10—nephrolithiasis	0.000257	0.00244	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RGS14—nephrolithiasis	0.000252	0.00239	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—DGKH—nephrolithiasis	0.00025	0.00237	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000237	0.00225	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000237	0.00225	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000229	0.00217	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GRHPR—nephrolithiasis	0.000223	0.00211	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RGS14—nephrolithiasis	0.000219	0.00207	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GRHPR—nephrolithiasis	0.000218	0.00207	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000216	0.00205	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PTH—nephrolithiasis	0.00021	0.00199	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.000208	0.00197	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000199	0.00189	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AGXT—nephrolithiasis	0.000199	0.00188	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AGXT—nephrolithiasis	0.000194	0.00184	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PTH—nephrolithiasis	0.00019	0.0018	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00019	0.0018	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GRHPR—nephrolithiasis	0.000188	0.00178	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PTH—nephrolithiasis	0.000182	0.00173	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000181	0.00171	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—DGKH—nephrolithiasis	0.00017	0.00161	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00017	0.00161	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—APRT—nephrolithiasis	0.000169	0.0016	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—SLC26A1—nephrolithiasis	0.000169	0.0016	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GRHPR—nephrolithiasis	0.000169	0.0016	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AGXT—nephrolithiasis	0.000167	0.00159	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PTH—nephrolithiasis	0.000165	0.00157	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—APRT—nephrolithiasis	0.000165	0.00157	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—SLC26A1—nephrolithiasis	0.000165	0.00157	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000165	0.00156	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000155	0.00147	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GRHPR—nephrolithiasis	0.000154	0.00146	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AGXT—nephrolithiasis	0.00015	0.00142	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000148	0.0014	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—DGKH—nephrolithiasis	0.000148	0.0014	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000147	0.00139	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—APRT—nephrolithiasis	0.000142	0.00135	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—SLC26A1—nephrolithiasis	0.000142	0.00135	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000138	0.00131	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AGXT—nephrolithiasis	0.000137	0.0013	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GRHPR—nephrolithiasis	0.000131	0.00124	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	0.000128	0.00121	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—APRT—nephrolithiasis	0.000128	0.00121	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—APRT—nephrolithiasis	0.000125	0.00118	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000125	0.00118	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CHRM3—nephrolithiasis	0.000123	0.00117	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AQP1—nephrolithiasis	0.00012	0.00114	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AQP1—nephrolithiasis	0.000118	0.00112	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000117	0.00111	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000117	0.00111	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AGXT—nephrolithiasis	0.000117	0.00111	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	0.000116	0.0011	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—APRT—nephrolithiasis	0.000116	0.0011	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTH—nephrolithiasis	0.000112	0.00107	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CHRM3—nephrolithiasis	0.000109	0.00103	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000107	0.00101	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CHRM3—nephrolithiasis	0.000106	0.00101	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AQP1—nephrolithiasis	0.000101	0.000961	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000101	0.00096	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	9.95e-05	0.000943	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APRT—nephrolithiasis	9.95e-05	0.000943	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTH—nephrolithiasis	9.77e-05	0.000925	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CHRM3—nephrolithiasis	9.17e-05	0.000869	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AQP1—nephrolithiasis	9.1e-05	0.000862	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AGXT—nephrolithiasis	9.03e-05	0.000856	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AQP1—nephrolithiasis	8.88e-05	0.000842	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AQP1—nephrolithiasis	8.37e-05	0.000793	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AQP1—nephrolithiasis	8.3e-05	0.000786	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CHRM3—nephrolithiasis	8.23e-05	0.00078	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CHRM3—nephrolithiasis	8.03e-05	0.000761	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APRT—nephrolithiasis	7.68e-05	0.000728	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	7.68e-05	0.000728	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CHRM3—nephrolithiasis	7.57e-05	0.000717	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CHRM3—nephrolithiasis	7.51e-05	0.000711	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AQP1—nephrolithiasis	7.09e-05	0.000672	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CHRM3—nephrolithiasis	6.41e-05	0.000608	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SPP1—nephrolithiasis	5.65e-05	0.000535	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AQP1—nephrolithiasis	5.47e-05	0.000519	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CHRM3—nephrolithiasis	4.95e-05	0.000469	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SPP1—nephrolithiasis	4.9e-05	0.000465	CbGpPWpGaD
